**eTable 1B:** Sensitivity analyses using between-individual analyses for the outcome of suicide and within-individual analyses for the outcome of self-harm.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | **(5) 90-days  treatment periods\*** | |  | **(6) Diagnose  prior to 1995\*** | |  | **(7) Probable deliberate  self-harm as outcome\*** | |
|  |  |  |  | n | Basic adjusted  Hazard ratio (95% CI) |  | n | Basic adjusted  Hazard ratio (95% CI) |  | n | Basic adjusted  Hazard ratio (95% CI) |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Suicide - between individual** | |  |  |  |  |  |  |  |  |  |  |
|  | Lithium |  |  | 94 | **0.50 (0.39-0.63) \*\*\*** |  | 87 | **0.50 (0.40-0.62) \*\*\*** |  |  |  |
|  | No treatment |  |  | 310 | 1 [ref] |  | 735 | 1 [ref] |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | Valproate |  |  | 41 | 1.09 (0.78-1.52) |  | 26 | 0.94 (0.63-1.41) |  |  |  |
|  | No treatment |  |  | 310 | 1 [ref] |  | 735 | 1 [ref] |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | Other mood stabilizers |  |  | 110 | 1.19 (0.95-1.49) |  | 85 | 1.16 (0.91-1.48) |  |  |  |
|  | No treatment |  |  | 310 | 1 [ref] |  | 735 | 1 [ref] |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | Antipsychotics |  |  | 156 | **1.35 (1.10-1.67) \*\*** |  | 131 | **1.66 (1.34-2.05) \*\*\*** |  |  |  |
|  | No treatment |  |  | 310 | 1 [ref] |  | 735 | 1 [ref] |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Self-harm - within individual** | |  |  |  |  |  |  |  |  |  |  |
|  | Lithium |  |  | 592 | **0.78 (0.64-0.96) \*** |  | 568 | 0.74 (0.61-0.89) \*\* |  | 1 451 | 1.01 (0.89-1.15) |
|  | No treatment |  |  | 1 338 | 1 [ref] |  | 2 607 | 1 [ref] |  | 3 358 | 1 [ref] |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | Valproate |  |  | 232 | 0.86 (0.65-1.13) |  | 172 | 0.80 (0.60-1.07) |  | 451 | **0.83 (0.70-1.00) \*** |
|  | No treatment |  |  | 1 338 | 1 [ref] |  | 2 607 | 1 [ref] |  | 3 358 | 1 [ref] |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | Other mood stabilizers |  |  | 618 | 0.90 (0.73-1.09) |  | 491 | 0.93 (0.76-1.13) |  | 1 037 | 1.00 (0.88-1.15) |
|  | No treatment |  |  | 1 338 | 1 [ref] |  | 2 607 | 1 [ref] |  | 3 358 | 1 [ref] |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | Antipsychotics |  |  | 944 | 0.92 (0.77-1.10) |  | 740 | 1.02 (0.86-1.20) |  | 1 687 | **1.12 (1.01-1.25) \*** |
|  | No treatment |  |  | 1 338 | 1 [ref] |  | 2 607 | 1 [ref] |  | 3 358 | 1 [ref] |

\* Following sensitivity analyses were conducted:

*Sensitivity analysis 4*: Individuals who were not in monotherapy were exclude during the periods where they were in therapy with several of the examined drugs. *Sensitivity analysis 5*: Treatment period was fixed to 90 days. If a new prescription was redeemed within the 90 days, the person was considered as in treatment for another 90 days from the date of the new redemption. *Sensitivity analysis 6*: All persons alive with a diagnosis of bipolar were included in the analysis even if they did not have a contact diagnose within the study period. *Sensitivity analysis 7*: The definition of self-harm was widened to a include probable self-harm as defined in the outcome section. All models were adjusted for sex, calendar period, and age group.

Abbreviations: NA: Not applicable. P-values: \*\*\*: p < 0.001, \*\*: p < 0.01: \*: p<0.0